A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Study Details

Main inclusion criteria:

  1. Chronic AD for at least 2 years with EASI ≥ 16 and IGA score ≥ 3. AD involvement ≥ 10% of body surface area.
     
  2. Documented recent history (within 6 months) of inadequate response to TCS.
     
  3. Documented recent history (within 6 months) of inadequate response to TCI if the patient has been using TCI.
Sponsor(s)
Galderma
Principal Investigator(s)
Dr. Karl Saardi
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

5 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.